Trial Profile
To assess longterm efficacy and safety of omalizumab in patients with severe allergic asthma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Mar 2017
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma; Asthma
- Focus Adverse reactions; Therapeutic Use
- 20 Mar 2017 New trial record
- 01 Mar 2017 Results published in the Respiratory Medicine